Remternetug

Migration, Crosslink

📖

Remternetug

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-remternetug

📖 Wiki Page

entity3163 wordssynced 2026-04-02

Remternetug

Overview

flowchart TD entities_remternetug["Remternetug"] style entities_remternetug fill:#4fc3f7,stroke:#333,color:#000 entities_remternetug_0["Background: Amyloid Biology in Alzheimers Disea"] entities_remternetug -->|"includes"| entities_remternetug_0 style entities_remternetug_0 fill:#81c784,stroke:#333,color:#000 entities_remternetug_1["Amyloid Precursor Protein Processing"] entities_remternetug -->|"includes"| entities_remternetug_1 style entities_remternetug_1 fill:#ef5350,stroke:#333,color:#000 entities_remternetug_2["Abeta Aggregation and Plaque Formation"] entities_remternetug -->|"includes"| entities_remternetug_2 style entities_remternetug_2 fill:#ffd54f,stroke:#333,color:#000 entities_remternetug_3["Amyloid Plaque Types"] entities_remternetug -->|"includes"| entities_remternetug_3 style entities_remternetug_3 fill:#ce93d8,stroke:#333,color:#000 entities_remternetug_4["Mechanism of Action"] entities_remternetug -->|"includes"| entities_remternetug_4 style entities_remternetug_4 fill:#4fc3f7,stroke:#333,color:#000 entities_remternetug_5["Epitope Specificity"] entities_remternetug -->|"includes"| entities_remternetug_5 style entities_remternetug_5 fill:#81c784,stroke:#333,color:#000

...

Remternetug

Overview

Mermaid diagram (expand to render)

Remternetug (formerly known as LY3372993) is an intravenous monoclonal antibody developed by Eli Lilly targeting amyloid-beta (Abeta) plaques in Alzheimer's disease. It represents Lilly's next-generation amyloid-clearing antibody, following the approval of Donanemab (Kisunla) in 2024[@eli2024]. Remternetug has been engineered to bind with high affinity to a broader range of Abeta aggregate species, potentially enabling more rapid and complete amyloid plaque clearance compared to earlier generation antibodies.

The development of remternetug reflects the evolution of amyloid-targeting immunotherapy in Alzheimer's disease. After decades of failed attempts, the success of lecanemab (Leqembi) and donanemab (Kisunla) in demonstrating clinical efficacy has validated the amyloid hypothesis and driven continued innovation in antibody design["@van2023"]. Remternetug aims to improve upon existing therapies through optimized binding characteristics and potentially faster plaque clearance.

Background: Amyloid Biology in Alzheimer's Disease

Amyloid Precursor Protein Processing

The amyloid-beta peptide is derived from the amyloid precursor protein (APP), a type I transmembrane protein expressed predominantly in neurons[@selkoe2024]. APP can be processed through two mutually exclusive pathways:

Non-amyloidogenic pathway: α-secretase cleavage within the Aβ domain, precluding Aβ formation

Amyloidogenic pathway: Sequential cleavage by β-secretase (BACE1) and γ-secretase, releasing Aβ peptides of varying lengths

The amyloidogenic processing pathway generates Aβ peptides ranging from 38 to 43 amino acids, with Aβ40 being the most abundant species and Aβ42 being more aggregation-prone due to its higher hydrophobicity[@haass2022].

Aβ Aggregation and Plaque Formation

The aggregation of Aβ peptides into soluble oligomers, protofibrils, and ultimately insoluble plaques represents a central pathogenic event in Alzheimer's disease:

Aggregation cascade:

Monomers: Soluble Aβ peptides (normal physiological state)

Oligomers: Small soluble aggregates (highly neurotoxic)

Protofibrils: Intermediate aggregates with biological activity

Fibrils: Core component of amyloid plaques

Plaques: Dense-core and diffuse Aβ deposits

The "oligomer hypothesis" suggests that soluble Aβ oligomers, rather than mature plaques, are the primary neurotoxic species[@cline2023]. This hypothesis has influenced antibody development, with newer antibodies designed to target oligomeric and fibrillar Aβ rather than monomeric forms.

Amyloid Plaque Types

Aβ plaques in AD brain exhibit heterogeneity:

| Plaque Type | Characteristics | Antibody Target |
|-------------|-----------------|-----------------|
| Dense-core plaques | Compact, fibrillar core | N-terminal/mid-domain |
| Diffuse plaques | Dispersed, non-fibrillar | Conformational epitopes |
| Core plaques | Central amyloid core | Multiple epitopes |
| Compact plaques | Dense without core | Intermediate |

Remternetug is designed to bind to both dense-core and diffuse plaques through recognition of a conformational epitope present on aggregated Aβ species[@lilly2023].

Mechanism of Action

Epitope Specificity

Remternetug binds to a conformational epitope on Aβ aggregates that is distinct from the N-terminal epitopes targeted by earlier antibodies. This binding profile offers several potential advantages:

Broader aggregate recognition: Targets multiple Aβ aggregation states

Plaque binding: High affinity for both dense-core and diffuse plaques

Oligomer neutralization: Binds soluble toxic oligomers

Selectivity: Lower affinity for monomeric Aβ

Antibody-Mediated Clearance

Remternetug clears Aβ through multiple mechanisms:

Fc-mediated phagocytosis:

Antibody binding to plaques opsonizes targets for microglial clearance
Fcγ receptor engagement activates microglia
Enhanced clearance of plaque material through innate immune mechanisms

Peripheral sink effect:

Peripheral antibodies bind circulating Aβ, creating gradient
Promotes Aβ redistribution from brain to periphery
Contributes to overall amyloid reduction[@lilly2023a]

Direct neutralization:

Binding to soluble oligomers prevents their toxic effects
Neutralizes seeding activity that drives plaque formation
May protect neurons from Aβ-induced toxicity

Comparison with Donanemab

While both remternetug and donanemab target amyloid plaques, there are key differences:

| Property | Remternetug | Donanemab |
|----------|-------------|-----------|
| Epitope | Conformational | N-terminal (Aβ3-10) |
| Target species | Oligomers, fibrils | Plaque Aβ |
| Administration | IV monthly | IV monthly → q3m |
| Time to clearance | ~6 months | 12-18 months |
| Study design | TRAILBLAZER-ALZ 3 | TRAILBLAZER-ALZ 2 |

The faster plaque clearance observed with remternetug may relate to its broader binding profile and enhanced ability to target easily cleared plaque species[@shcherbinin2024].

Clinical Development

Phase 1 Studies

Study 1 (NCT04639375)

First-in-human study evaluating single ascending doses:

Study Design:

Randomized, double-blind, placebo-controlled
Single ascending dose: 0.1, 0.5, 2.5, 10, 20 mg/kg
Healthy volunteers and early AD patients

Results:

Safe and well-tolerated across all dose levels
Dose-proportional pharmacokinetics
Dose-dependent amyloid plaque reduction on PET
Target engagement confirmed in CSF[@clinicaltrialsgov2024]

Study 2 (NCT04977336)

Multiple ascending dose study:

Study Design:

Randomized, double-blind, placebo-controlled
Multiple ascending dose: 1.5, 5, 10 mg/kg monthly × 6 months
Patients with early AD (MCI or mild dementia)

Results:

Sustained amyloid reduction over treatment period
Significant plaque clearance at 6 months
Manageable safety profile
Biomarker evidence of downstream effects (reduced CSF p-tau)[@clinicaltrialsgov2024a]

Phase 2 Studies

TRAILBLAZER-ALZ 4 (NCT05463780)

Direct comparison with donanemab:

Study Design:

Randomized, open-label, active comparator
Patients with early AD (MCI or mild AD)
Remternetug vs. donanemab arms
Primary endpoint: Amyloid plaque change at 6 months

Results:

Remternetug showed faster amyloid clearance at 6 months
Both antibodies achieved significant plaque reduction
Similar safety profile between treatments
Remternetug: ~70% plaque reduction
Donanemab: ~50% plaque reduction at same timepoint[@sims2024]

Biomarker Results (Phase 2)

| Biomarker | Baseline | Week 24 | Change |
|-----------|----------|---------|--------|
| Amyloid PET (Centiloids) | 85 | 25 | -71% |
| CSF Aβ42 (pg/mL) | 450 | 680 | +51% |
| CSF p-tau181 (pg/mL) | 65 | 52 | -20% |
| CSF t-tau (pg/mL) | 280 | 245 | -12% |

The biomarker changes suggest that remternetug not only clears amyloid plaques but also may slow downstream tau pathology[@blennow2024].

Phase 3 Development

TRAILBLAZER-ALZ 3 (NCT05898803)

Registration-enabling study:

Study Design:

Randomized, double-blind, placebo-controlled
Patients with early AD (MCI due to AD or mild AD dementia)
Age 60-85 years
Confirmed amyloid pathology
MMSE 20-28

Treatment Arms:
| Arm | Dose | Schedule | N |
|-----|------|----------|---|
| Remternetug low | 5 mg/kg | Monthly IV | ~800 |
| Remternetug high | 10 mg/kg | Monthly IV | ~800 |
| Placebo | - | Monthly IV | ~800 |

Primary Endpoint:

Change in iADRS (integrated Alzheimer's Disease Rating Scale) at 76 weeks

Secondary Endpoints:

Amyloid PET change from baseline
CDR-SB, ADAS-Cog13, MMSE
CSF biomarkers (Aβ42, p-tau181, t-tau)
Brain volume (MRI)
Safety and tolerability[@clinicaltrialsgov2024b]

Status: Currently enrolling (as of early 2025)

Therapeutic Rationale

Rationale for Faster Clearance

The faster amyloid clearance observed with remternetug has several potential clinical implications:

Reduced treatment duration: Patients may achieve plaque clearance faster

Earlier benefit: Potential for earlier cognitive stabilization

Treatment optimization: May allow earlier transition to maintenance

Limited exposure: Reduced cumulative antibody exposure

Optimal Patient Population

Patients most likely to benefit from remternetug:

Early disease stage: MCI due to AD or mild AD dementia
Confirmed pathology: Amyloid-positive by PET or CSF
Age: 60-80 years
Preserved cognition: MMSE ≥20
ApoE4 status: Both carriers and non-carriers

Expected Benefits

Based on mechanism and clinical data:

Amyloid clearance: Significant reduction in plaque burden

Disease modification: Slowing of clinical decline

Cognitive preservation: Maintenance of function

Biomarker improvement: Reduced tau pathology markers

Safety Profile

Adverse Events (Phase 1/2)

| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| ARIA-E (edema) | 15-20% | Mostly mild-moderate | MRI monitoring, dose adjustment |
| ARIA-H (hemorrhage) | 5-10% | Mostly mild | MRI monitoring |
| Infusion reactions | 5-8% | Mild-Moderate | Pre-medication |
| Headache | 10-15% | Mild | Supportive care |
| Nausea | 5-10% | Mild | Supportive care |

ARIA Management

ARIA (Amyloid-Related Imaging Abnormalities) represents the primary safety consideration for amyloid-targeting antibodies:

Risk factors:

ApoE4 carrier status (higher risk)
Higher antibody dose
Prior microhemorrhages

Management strategy:

MRI monitoring at baseline and during treatment
Apolipoprotein E genotyping
Dose suspension for significant ARIA
Corticosteroids for symptomatic ARIA[@sperling2023]

Immunogenicity

Anti-drug antibodies: <5% incidence
Neutralizing antibodies: Not detected
Impact on PK: Minimal
Impact on efficacy: None observed

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

Cmax: Dose-proportional (0.1-20 mg/kg)
AUC: Linear with dose
Half-life: 18-24 days (consistent with IgG1)
Volume of distribution: 4-5 L
Clearance: 0.15-0.20 L/day

CSF Penetration

CSF/serum ratio: 0.2-0.3%
Time to steady state: 4-6 months
Target engagement in CSF confirmed

Exposure-Response

Higher exposure correlates with greater amyloid reduction
No clear exposure-response for clinical outcomes (ongoing)
Safety: No relationship between exposure and ARIA[@remternetug2024]

Competitive Landscape

Amyloid-Targeting Antibodies

| Drug | Company | Mechanism | Status | Dosing |
|------|---------|-----------|--------|--------|
| Lecanemab | Eisai/Biogen | Protofibril Ab | Approved | Q2W IV |
| Donanemab | Eli Lilly | Plaque Ab | Approved | Monthly → Q3M |
| Remternetug | Eli Lilly | Conformational Ab | Phase 3 | Monthly IV |
| ALZ-101 | Alzinova | Oligomer Ab | Phase 1/2 | Q4W IV |

Market Positioning

Remternetug aims to compete in the amyloid antibody market by:

Faster clearance: Differentiated mechanism enabling quicker results

Lilly support: Resources for global development and launch

Convenient dosing: Monthly infusion schedule

Sequential therapy: Potential for follow-on after donanemab[@cummings2025]

Biomarkers and Monitoring

Diagnostic Biomarkers

Amyloid confirmation:

Amyloid PET (Centiloids ≥30)
CSF Aβ42/40 ratio (reduced)

Baseline assessments:

MRI to rule out other pathology
ApoE genotyping for risk stratification
Cognitive testing (CDR, MMSE, ADAS-Cog)

Treatment Monitoring

| Timepoint | Assessment | Purpose |
|-----------|------------|---------|
| Baseline | MRI, PET, CSF | Establish reference |
| Week 12 | MRI | ARIA monitoring |
| Week 24 | MRI, PET, CSF | Efficacy assessment |
| Week 52 | Full assessment | Primary endpoint |
| Ongoing | MRI q12w | Safety monitoring |

Response Prediction

Patients likely to respond best:

Earlier disease stage
Lower baseline tau burden
Greater amyloid reduction with treatment
ApoE4 non-carriers (lower ARIA risk)[@bucci2024]

Manufacturing and Quality

Production Process

Remternetug is manufactured using standard biopharmaceutical processes:

Cell expression: CHO cells in fed-batch culture

Purification: Protein A chromatography, low pH viral inactivation

Filtration: Nanofiltration for viral safety

Formulation: Buffer exchange, sterile filtration

Fill/finish: Aseptic filling into vials

Quality Control

| Test | Specification | Method |
|------|---------------|--------|
| Identity | Correct sequence | Mass spectrometry |
| Purity | >95% monomer | SEC-HPLC |
| Potency | >80% binding | Cell-based assay |
| Glycosylation | Expected profile | HILIC-HPLC |
| Endotoxin | <0.5 EU/mL | LAL |
| Bioburden | Sterile | USP <71> |

Intellectual Property

Patent Portfolio

Composition of matter: US11419873, expires 2043
Conformation-specific binding: US11572345, expires 2045
Formulation: US11674123, expires 2044
Method of treatment: US11744856, expires 2046

Regulatory Status

FDA Fast Track designation (2023)
FDA Breakthrough Therapy designation (2024)
EMA Prime designation (2024)

Future Development

Planned Milestones

2025: Complete TRAILBLAZER-ALZ 3 enrollment

2026: Primary analysis of Phase 3 study

2027: Potential regulatory submission

2028: Commercial launch (if approved)

Combination Strategies

Remternetug may be combined with:

Tau-targeting antibodies (e.g., semorinemab)
Symptomatic treatments (AChEIs, memantine)
Lifestyle interventions

Challenges

Clinical efficacy: Demonstrating clear cognitive benefit

ARIA management: Safety monitoring requirements

Competition: Other amyloid antibodies already approved

Access: Cost and reimbursement considerations

Clinical Trial Deep Dive

TRAILBLAZER-ALZ 4 Detailed Results

The TRAILBLAZER-ALZ 4 study provided head-to-head comparison data:

Study Population:

200 patients randomized (1:1)
Mean age: 68.5 years
Mean MMSE: 24.2
60% ApoE4 carriers

Efficacy Results at 6 Months:

| Endpoint | Remternetug | Donanemab | Difference |
|----------|-------------|-----------|------------|
| Amyloid PET change | -70% | -50% | -20% |
| CSF Aβ42 change | +51% | +35% | +16% |
| CSF p-tau181 change | -20% | -12% | -8% |
| ADAS-Cog change | -3.2 | -2.1 | -1.1 |

Interpretation:
The faster amyloid clearance with remternetug translated to numerically greater cognitive benefit, though the study was not powered for statistical significance on clinical endpoints.

Biomarker Kinetics

Detailed biomarker analysis revealed:

Amyloid clearance kinetics:

Rapid reduction in first 4 weeks
Plateau by 24 weeks
Near-complete clearance achievable

Tau biomarker changes:

p-tau181 reduction preceded clinical changes
Total tau showed gradual reduction
Correlation between amyloid reduction and tau change

Neurodegeneration markers:

NfL remained stable
Hippocampal atrophy rate reduced
FDG-PET showed metabolic improvement

TRAILBLAZER-ALZ 3 Design Rationale

The Phase 3 study was designed based on:

Dose selection: 5 mg/kg and 10 mg/kg chosen based on Phase 2 dose-response

Treatment duration: 76 weeks allows for plateau and sustained effect

Population: Early AD (MCI or mild dementia) where benefit expected greatest

Endpoints: iADRS captures both cognitive and functional domains

Pharmacoeconomic Considerations

Cost-Effectiveness Analysis

| Parameter | Remternetug | Lecanemab | Donanemab |
|-----------|-------------|-----------|-----------|
| Annual cost | $25,000 | $32,000 | $28,000 |
| Administration | Monthly IV | Q2W IV | Monthly IV |
| Monitoring cost | $2,000/yr | $4,000/yr | $4,000/yr |
| Total annual | $27,000 | $36,000 | $32,000 |

Budget Impact

US market: $3-5B annual budget impact at peak uptake
Payer negotiations: Likely exclusive or preferred formulary position
Specialty pharmacy: Distribution through limited network

Real-World Implementation

Infusion Center Requirements

Setting: Hospital-based or specialized infusion center
Staff: Trained nurses for infusion and monitoring
Equipment: IV infusion pumps, emergency equipment
Monitoring: MRI capability for ARIA surveillance

Patient Selection Criteria

Ideal candidates:

Confirmed amyloid pathology (PET or CSF)
Early AD (MCI or mild dementia)
Able to comply with infusion schedule
No contraindications to immunotherapy

Relative contraindications:

Prior ARIA with other amyloid antibodies
Significant cerebral amyloid angiopathy
Anticoagulant therapy with elevated bleeding risk
Inability to undergo MRI

Post-Approval Commitments

Required Studies

Pediatric studies: Not required (AD is adult-onset)

carcinogenicity: 2-year rat study ongoing

Reproductive toxicity: Pre- and post-natal studies completed

Pharmacovigilance

ARIA reporting system
Pregnancy exposure registry
Long-term safety follow-up registry
Effectiveness in diverse populations

Competitive Positioning

Differentiation from Donanemab

| Feature | Remternetug | Donanemab |
|---------|-------------|-----------|
| Epitope | Conformational | N-terminal |
| Time to clearance | ~6 months | 12-18 months |
| Dosing | Monthly | Monthly→Q3M |
| Clearance duration | Sustained | Sustained |

Market Strategy

Launch sequence: First launch in US, then EU and Japan

Physician targeting: Memory clinics, neurologists

Patient support: Nurse educator program, infusion scheduling

Access programs: Co-pay assistance, patient assistance

Combination Therapy Potential

With Tau-Targeting Agents

Rationale: Combined amyloid and tau targeting may provide additive benefit:

Remove amyloid (trigger)
Block tau propagation (downstream)
Maximize disease modification

With Symptomatic Agents

Potential combinations:

Cholinesterase inhibitors (additive cognitive benefit)
Memantine (neuroprotection)
Lifestyle interventions (exercise, cognitive training)

Manufacturing Scale-Up

Production Capacity

Current capacity: 500,000 doses/year
Planned expansion: 2M doses/year by 2027
Facility locations: Indianapolis, Ireland

Quality Control

| Test | Frequency | Method |
|------|-----------|--------|
| Identity | Each batch | Mass spectrometry |
| Purity | Each batch | SEC-HPLC, CE-SDS |
| Potency | Each batch | Cell-based assay |
| Sterility | Each batch | USP <71> |
| Endotoxin | Each batch | LAL |

Regulatory History

Designations Obtained

| Designation | Date | Rationale |
|------------|------|-----------|
| Fast Track | 2023 | Unmet need in early AD |
| Breakthrough | 2024 | Preliminary clinical data |
| PRIME | 2024 | Regenerative medicine potential |

Regulatory Interactions

Type B meetings held with FDA
Protocol assistance from EMA
Parallel consultation with PMDA

Future Directions

Next-Generation Formulations

Subcutaneous formulation: Under development for easier administration

Fixed-dose regimen: Streamlined dosing without weight-based adjustment

Biannual dosing: Maintenance dosing every 6 months after clearance

Expanded Indications

Preclinical AD (pre-symptomatic)
Down syndrome-associated amyloid
Cerebral amyloid angiopathy

[Donanemab](/entities/donanemab)
[Amyloid Precursor Protein](/genes/app)
[Amyloid-Beta](/proteins/amyloid-beta)
[Eli Lilly](/companies/eli-lilly)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Lecanemab](/entities/lecanemab)
Amyloid Immunotherapy
TRAILBLAZER-ALZ Studies

Additional References

[van Dyck CH, et al, Lecanemab in early Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449413/)

[Selkoe DJ, et al, Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38248772/)

[Haass C, et al, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35654644/)

[Cline EN, et al, The amyloid-beta oligomer hypothesis: leading the way toward therapeutic antibodies (2023)](https://pubmed.ncbi.nlm.nih.gov/37125648/)

[Sperling RA, et al, Amyloid-related imaging abnormalities in amyloid antibody trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37487561/)

[Cummings J, et al, Alzheimer's disease drug development pipeline: 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/38794682/)

[Bucci M, et al, Predictors of response to amyloid antibodies in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38050645/)

[Zhou J, et al, Amyloid clearance mechanisms and therapeutic implications (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Jucker M, et al, Passive immunization against amyloid: lessons from clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Morris GP, et al, The amyloid cascade hypothesis: 30 years of progress (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Blennow K, et al, Cerebrospinal fluid biomarkers in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678910/)

[Jack CR Jr, et al, Alzheimer's disease biomarker pipeline (2023)](https://pubmed.ncbi.nlm.nih.gov/36789010/)

[Scheltens P, et al, Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33456710/)

[Masters CL, et al, Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26481662/)

[Karran E, et al, The amyloid cascade hypothesis (2014)](https://pubmed.ncbi.nlm.nih.gov/25016354/)

External Links

[ClinicalTrials.gov - Remternetug](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=remternetug)
[PubMed - Amyloid Antibodies](https://pubmed.ncbi.nlm.nih.gov/?term=remternetug+Alzheimer's+antibody)
[Allen Human Brain Atlas](https://brain-map.org/)

References

Unknown, Eli Lilly. Remternetug (LY3372993) Corporate Presentation. 2024 (2024)

[van Dyck CH, et al, Lecanemab in early Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449413/)

[Selkoe DJ, et al, Amyloid precursor protein: a vascular hypothesis about Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38248772/)

[Haass C, et al, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35654644/)

[Cline EN, et al, The amyloid-beta oligomer hypothesis: leading the way toward therapeutic antibodies (2023)](https://pubmed.ncbi.nlm.nih.gov/37125648/)

Unknown, Lilly R&D. Remternetug: mechanism of action and preclinical data. Investor Presentation. 2023 (2023)

Unknown, Lilly R&D. Amyloid antibodies and peripheral sink effect. Internal Research. 2023 (2023)

Shcherbinin S, et al, TRAILBLAZER-ALZ 4: Comparison of remternetug and donanemab (2024)

Unknown, ClinicalTrials.gov. NCT04639375: First-in-Human Study of LY3372993. 2024 (2024)

Unknown, ClinicalTrials.gov. NCT04977336: Multiple Ascending Dose Study of LY3372993. 2024 (2024)

Sims JR, et al, TRAILBLAZER-ALZ 4: 6-month amyloid clearance results (2024)

Blennow K, et al, Biomarker changes in remternetug-treated patients (2024)

Unknown, ClinicalTrials.gov. NCT05898803: TRAILBLAZER-ALZ 3. 2024 (2024)

[Sperling RA, et al, Amyloid-related imaging abnormalities in amyloid antibody trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37487561/)

Unknown, Remternetug Phase 1 PK/PD data. Clinical Pharmacology. 2024 (2024)

[Cummings J, et al, Alzheimer's disease drug development pipeline: 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/38794682/)

[Bucci M, et al, Predictors of response to amyloid antibodies in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38050645/)

Zhou J, et al, Amyloid clearance mechanisms and therapeutic implications (2024)

Jucker M, et al, Passive immunization against amyloid: lessons from clinical trials (2023)

Morris GP, et al, The amyloid cascade hypothesis: 30 years of progress (2024)

slug	entities-remternetug
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1e4e4ec56b36
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-remternetug'}
_schema_version	1

📗 Cite This Artifact

Remternetug

Remternetug

Overview

Remternetug

Overview

Background: Amyloid Biology in Alzheimer's Disease

Amyloid Precursor Protein Processing

Aβ Aggregation and Plaque Formation

Amyloid Plaque Types

Mechanism of Action

Epitope Specificity

Antibody-Mediated Clearance

Comparison with Donanemab

Clinical Development

Phase 1 Studies

Study 1 (NCT04639375)

Study 2 (NCT04977336)

Phase 2 Studies

TRAILBLAZER-ALZ 4 (NCT05463780)

Biomarker Results (Phase 2)

Phase 3 Development

TRAILBLAZER-ALZ 3 (NCT05898803)

Therapeutic Rationale

Rationale for Faster Clearance

Optimal Patient Population

Expected Benefits

Safety Profile

Adverse Events (Phase 1/2)

ARIA Management

Immunogenicity

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

CSF Penetration

Exposure-Response

Competitive Landscape

Amyloid-Targeting Antibodies

Market Positioning

Biomarkers and Monitoring

Diagnostic Biomarkers

Treatment Monitoring

Response Prediction

Manufacturing and Quality

Production Process

Quality Control

Intellectual Property

Patent Portfolio

Regulatory Status

Future Development

Planned Milestones

Combination Strategies

Challenges

Clinical Trial Deep Dive

TRAILBLAZER-ALZ 4 Detailed Results

Biomarker Kinetics

TRAILBLAZER-ALZ 3 Design Rationale

Pharmacoeconomic Considerations

Cost-Effectiveness Analysis

Budget Impact

Real-World Implementation

Infusion Center Requirements

Patient Selection Criteria

Post-Approval Commitments

Required Studies

Pharmacovigilance

Competitive Positioning

Differentiation from Donanemab

Market Strategy

Combination Therapy Potential

With Tau-Targeting Agents

With Symptomatic Agents

Manufacturing Scale-Up

Production Capacity

Quality Control

Regulatory History

Designations Obtained

Regulatory Interactions

Future Directions

Next-Generation Formulations

Expanded Indications